Mesoblast (ASX:MSB) has welcomed new research showing that its allogeneic cell therapy remestemcel-L delivers superior clinical outcomes compared with ruxolitinib for patients with steroid-refractory acute graft versus host disease.
New analysis finds Mesoblast’s Remestemcel-L outperforms ruxolitinib in severe GvHD
December 14, 2025 Australian Biotech
Latest Video
New Stories
-
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News -
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 - - Australian Biotech -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 - - Australian Biotech -
The TGA's new guidance risks blurring the line between advertising and journalism
November 18, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 18, 2026 - - Latest News -
Hungary's Gedeon Richter offers $604 million for Mayne Pharma
November 18, 2026 - - Latest News

